Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. 1.7 million new HIV infections were reported globally in 2019 and 38 million people were living with HIV, according to the World Health Organization. "The market will infer that GSK and ViiV are left out in the cold here, supporting our long-standing concerns over the longer term outlook for GSK's HIV franchise," Citi analyst Andrew Baum said.
up 52.17% of people living with HIV, according to the volunteered reporting.
( z0 say :ARG0 ( z1 report :ARG1-of ( z2 volunteer ) ) :ARG1 ( z3 up :ARG3 ( z4 include :ARG1 ( z5 person ) :ARG2 ( z6 person :ARG0-of ( z7 live :ARG1 ( z8 disease :name ( z9 name :op "HIV" ) ) ) ) :ARG3 ( z10 percentage-entity :value 52.17 ) ) ) )
(z0 / say-01
    :ARG0 (z1 / report-01
              :ARG1-of (z2 / volunteer-01))
    :ARG1 (z3 / up-02
              :ARG3 (z4 / include-91
                        :ARG1 (z5 / person)
                        :ARG2 (z6 / person
                                  :ARG0-of (z7 / live-02
                                               :ARG1 (z8 / disease
                                                         :name (z9 / name
                                                                   :op1 "HIV"))))
                        :ARG3 (z10 / percentage-entity
                                   :value 52.17))))
up 52.17 % of people living with HIV , according to the volunteered reporting .
z3 :ARG3 z4
z4 :ARG3 z10
z10 :value 0
z4 :ARG1 z5
z4 :ARG2 z6
z6 :ARG0-of z7
z7 :ARG1 z8
z8 :name z9
z9 :op1 1
z0 :ARG1 z3
z1 :ARG1-of z2
z0 :ARG0 z1